The early response of renal cell carcinoma to tyrosine kinase inhibitors (sunitinib and sorafenib) evaluated by FDG PET/CT.
Phase of Trial: Phase IV
Latest Information Update: 16 Dec 2015
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 16 Dec 2015 New trial record